Onyx Pharmaceuticals competitors

Mike McMullen is Agilent’s CEO-elect. He will assume the CEO position in March 2015 when William (Bill) Sullivan takes an advisory role until his retirement. As a first step in the CEO transition, McMullen has been named president and chief operating officer. McMullen has more than 30 years of industry experience and senior management experience at Agilent. He has been president of the company’s Chemical Analysis Group (CAG) since 2009, a role he still fills on an acting basis. As head of CAG, McMullen transformed the business, consistently delivering market-leading growth and profits. He championed strategic acquisitions and architected Agilent’s China strategy. He built the Agilent-wide Services business that has now been made one of Agilent’s three major businesses. McMullen has extensive experience working across Agilent’s businesses, and is recognized for his inspirational leadership style. He also has significant international experience, having lived in Japan, leading Agilent’s Japan field sales and support operations, and later adding responsibility for China field operations. McMullen joined Agilent’s predecessor, Hewlett-Packard Co., in 1984 as a financial analyst. He holds a bachelor's degree in economics and business administration from the University of Delaware and an MBA from Wharton Business School.

Mr. Norman D. Schwartz is Chairman of the Board, President, Chief Executive Officer of Bio Rad Laboratories Inc. Mr. Schwartz has been President and Chief Executive Officer since 2003 and Chairman of the Board since 2012. He was Vice President from 1989 to 2002, Group Manager, Life Science, from 1997 to 2002 and Group Manager, Clinical Diagnostics, from 1993 to 1997.

Jean-Jacques Bienaime is a Board Member at Biotechnology Innovation Organization - BIO, Director at INCYTE CORP, and Chairman/CEO at BioMarin Pharmaceutical Inc and is based in Novato, California. He has experience at Rhône Poulenc Rorer and has worked as President/CEO at GENENCOR INTERNATIONAL INC, Board Member at NeurogesX Inc, and Marketing Director at Genentech. Jean attended ESCP Europe, Ecole Superieure de Commerce de Paris between 1974 and 1976, and University of Pennsylvania.

Francis Aurelio deSouza (born December 2, 1970) is an American entrepreneur and business executive. He is the president and chief executive officer (CEO) of Illumina and a member of the Board of Directors of The Walt Disney Company.

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

Michael S. Weiss has served as the Company’s Executive Chairman, President and CEO since December 2011. Mr. Weiss is also currently a director of the Company. Mr. Weiss is a co-founder of, and has been a Managing Partner and Principal of Opus Point Partners since 2008. Mr. Weiss has also been the Executive Chairman, Strategic Development of Fortress Biotechnology since January 2014 and has served as Co-Vice Chairman of the Fortress Biotech Board of Directors since December 2013. Mr. Weiss earned his J.D. from Columbia Law School and his B.S. in Finance from The University at Albany. He began his professional career as a lawyer with Cravath, Swaine & Moore. In 1999, Mr. Weiss founded Access Oncology which was later acquired by Keryx Biopharmaceuticals (NASDAQ: KERX) in 2004. Following the merger, Mr. Weiss remained as CEO of Keryx and grew the company to close to a $1BB market capitalization company at its peak. While at Keryx, he raised over $150MM in equity capital through public and private offerings, executed a $100MM+ strategic alliance, negotiated multiple Special Protocol Assessments (“SPA”) agreements with the FDA and managed multiple large clinical trials.

Founder of Sirius XM radio and United Therapeutics. Progressive technologist and green energy advocate. Helicopter, fixed wing pilot.

Global leader in the oncology pharmaceutical sector having successfully developed, acquired and launched several multi-billion dollar oncology brands across multiple tumor types and therapeutic approaches. Over 3 decades of experience in US and International pharmaceutical development, product strategy, commercialization and business development; and, has cultivated an extensive network with specialists and companies developing new treatment approaches for patients living with cancer. Recently, founded Proventus Health Solutions, a company specializing in helping oncology biotech companies create greater value by integrating development and commercial considerations into a unified approach. A member of the board of directors for Verastem Oncology (VSTM) and Oncopeptides AB (ONCO).